End Stage Cancer Clinical Trial
Official title:
Using Wearable Device and Smart Phone to Improve Survival Prediction and Quality of Life in Patients Receiving Palliative Care
This study is going to use wearable devices and smartphones to collect physical data from terminal patients and build a survival predicting model for terminal patients with machine learning. Investigators hypothesize that continuous physical data monitoring could offer a hint to better predictability in end-of-life care.
Status | Recruiting |
Enrollment | 75 |
Est. completion date | April 30, 2023 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 105 Years |
Eligibility | Inclusion criteria - Age: 20 years old or older - Clinical diagnosis: cancer in terminal stage. Exclusion criteria - Cannot cooperate with use of wearable devices or smartphones. |
Country | Name | City | State |
---|---|---|---|
Taiwan | National Taiwan University Hospital | Taipei | |
Taiwan | National Taiwan University, Cancer Center | Taipei |
Lead Sponsor | Collaborator |
---|---|
National Taiwan University Hospital | National Taiwan University |
Taiwan,
Pavic M, Klaas V, Theile G, Kraft J, Tröster G, Blum D, Guckenberger M. Mobile Health Technologies for Continuous Monitoring of Cancer Patients in Palliative Care Aiming to Predict Health Status Deterioration: A Feasibility Study. J Palliat Med. 2020 May;23(5):678-685. doi: 10.1089/jpm.2019.0342. Epub 2019 Dec 23. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Comparison of AUC-ROC in survival prediction between machine learning model and Palliative Performance Scale (PPS) | Palliative performance scale (PPS) will be regularly assessed during the follow-up. The AUC-ROC of using PPS for survival prediction will be calculated and compared with the machine-learning model. | From date of enrollment until the date of death, or assessed up to 26 weeks. PPS are assessed every week. Death or survival is recorded at the time the case closed. | |
Other | Comparison of AUC-ROC in survival prediction between machine learning model and Glasgow Prognostic Score (GPS) | Glasgow Prognostic Score (GPS) will be assessed if C-reactive protein (CRP) and albumin are examined during the follow-up. The AUC-ROC using GPS for survival prediction will be calculated and compared with the machine-learning model. | GPS assessed retrospectively if data available. Death or survival is recorded at the time the case closed. | |
Other | Comparison of AUC-ROC in survival prediction between machine learning model and Palliative Prognostic Index (PPI) | Palliative Prognostic Index(PPI) will be regularly assessed during the follow-up. The AUC-ROC of using PPI for survival prediction will be calculated and compared with the machine-learning model. | From date of enrollment until the date of death, or assessed up to 26 weeks. PPI are assessed every week. Death or survival is recorded at the time the case closed. | |
Other | Comparison of AUC-ROC in survival prediction between machine learning model and Palliative Prognostic Score (PaP) | Palliative Prognostic Score (PaP) will be assessed if laboratory data available during the follow-up. The AUC-ROC of using PaP for survival prediction will be compared with the machine-learning model. | From date of enrollment until the date of death, or assessed up to 26 weeks. PaP assessed every week only if the laboratory data available. | |
Other | Time spent at medical service | If unexpected medical needs happen, investigators will record time spent at ER stay or hospital admission | Recorded when events happen or afterwards | |
Other | Duration between events | Investigators will record duration between events (death, unexpected medical needs, admission and discharge) or duration from enrollment to events, if they happen | From date of enrollment until the date of death, or assessed up to 26 weeks. Duration was calculated after cases closed. | |
Other | Overall survival and survival time | Investigators will record the overall survival and survival time from enrollment. | From date of enrollment until the date of death, or assessed up to 26 weeks. Calculated after all cases closed. | |
Other | Site of death | If patient died during the follow-up, investigator will record the site of death (at home or any other chosen place, in the hospital or ER). Other details will be recorded if the family or caregivers are willing to provide. | Assessed at the time the case closed, only if the patient died | |
Other | Tolerability and user experience to wearable devices | Investigator will ask and record any discomfort or side effect noted during the follow-up and at the end of the study. Investigator will survey for user experience of patients or caregivers at the end of the study. | Assessed at the time the case closed | |
Other | Relation between personal background and user experience of wearable devices | Personal background such as educational level, age, and previous use of technological product will be recorded. Investigator will explore the relation between these factors and the user experience. | Assessed at the time the case closed | |
Primary | Area Under the Receiver Operating Characteristic curve (AUC-ROC) of the machine-learning model to predict survival using wearable device parameters and clinical assessment | Measured data from wearable device and regular assessment (including medical condition, laboratory data, symptom, functional assessment) will be integrated to build one machine-learning model to predict patients' death or survival within specific time range. The primary outcome is to evaluate the Area Under the Receiver Operating Characteristic curve (AUC - ROC) of the machine-learning model in predicting patients' survival. | From date of enrollment until the date of death, or assessed up to 26 weeks. Wearable device parameters are collected continuously. Other clinical assessments are performed every week. Death or survival is recorded at the time the case closed. | |
Primary | Area Under the Receiver Operating Characteristic curve (AUC-ROC) of machine-learning model to predict unexpected medical needs using wearable device parameters and clinical assessment | Measured data from wearable device and regular assessment (including medical condition, laboratory data, symptom, functional assessment) will be integrated to build one machine-learning model to predict patient's unexpected medical needs (which is defined as emergency department visit or unplanned admission to hospital).
The primary outcome is to evaluate Area Under the Receiver Operating Characteristic curve (AUC-ROC) of the machine-learning model in predicting unexpected medical needs. |
From date of enrollment until the date of death, or assessed up to 26 weeks. Wearable device parameters are collected continuously. Other clinical assessments are performed every week. Events are recorded upon happening or afterwards. | |
Secondary | Correlation between symptoms and wearable device parameters | The severity of symptoms will be recorded by symptoms assessment scale (SAS). Investigators will explore the correlation between the wearable device parameters and symptoms. | From date of enrollment until the date of death, or assessed up to 26 weeks. Wearable device parameters are collected continuously. Symptoms assessed every week. | |
Secondary | Correlation between Australia-modified Karnofsky Performance Status (AKPS) and wearable device parameters | The functional status will be assessed by Australia-modified Karnofsky Performance Status (AKPS) during the follow-up. Investigators will explore the correlation between AKPS and wearable device parameters | From date of enrollment until the date of death, or assessed up to 26 weeks. Wearable device parameters are collected continuously. Functional status assessed every week. | |
Secondary | Correlation between palliative care phase and wearable device parameters | Evaluation of palliative care phases from the Palliative Care Outcomes Collaboration (PCOC) system will be assessed regularly. Investigators will explore the correlation between the palliative care phases and other parameters (wearable device parameters, symptoms, medical condition). | From date of enrollment until the date of death, or assessed up to 26 weeks. Wearable device parameters are collected continuously. Palliative care phase assessed every week. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03679182 -
Efficacy and Safety of Olanzapine for the Treatment of Nausea and Vomiting in Palliative Cancer Care
|
Phase 2 | |
Enrolling by invitation |
NCT05407844 -
Community Health Worker Based Intervention to Improve Palliative Care
|
N/A | |
Active, not recruiting |
NCT04942756 -
GLYPALCARE STUDY - Multicenter, Randomized Study for Evaluating Continuous Glucose Monitoring (CGM) by Using FreeStyle Libre 2 (FSL2) for Preventing Hyperglycemia/Hypoglycemia Crisis in Advanced Oncological Patients.
|
N/A | |
Completed |
NCT04821466 -
VR for Symptom Control and Wellbeing
|
N/A | |
Recruiting |
NCT04016038 -
Psychosocial Approach and Sedation Practices
|
||
Completed |
NCT02151214 -
Efficacy of Parenteral Nutrition in Patients at the Palliative Phase of Cancer.
|
N/A | |
Completed |
NCT04495530 -
Information Needs Around Parenteral nUTrition in Cancer
|
||
Completed |
NCT01912846 -
An Interactive Advance Care Planning Intervention to Facilitate a Good Death for Cancer Patients
|
N/A | |
Recruiting |
NCT06072612 -
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
|
Phase 3 | |
Recruiting |
NCT03387436 -
The "Hand-in-Hand Study": Improvement of Quality of Life in Palliative Cancer Patients Through Collaborative Advance Care Planning
|
N/A | |
Recruiting |
NCT04883879 -
Artificial Intelligence-based Mortality Prediction Among Cancer Patients in the Hospice Ward
|